Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Steece-Collier

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
NPJ Parkinson'S Disease|May 24, 2022
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in proteinJoseph R Patterson, Warren D Hirst, Jacob W Howe, et al.
Frontiers in Neuroscience|April 16, 2025
Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor functionSheila M Fleming, Sophia Scott, Edward J Hamad, et al.
NPJ Parkinson'S Disease|January 3, 2024
Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrilsJoseph R Patterson, Joseph Kochmanski, Anna C Stoll, et al.
JCI Insight|March 8, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's diseaseTracy A Cole, Hien Zhao, Timothy J Collier, et al.
Progress in Neurobiology|July 26, 2015
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F Bastide, Wassilios G Meissner, Barbara Picconi, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
NPJ Parkinson'S Disease|May 24, 2022
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in proteinJoseph R Patterson, Warren D Hirst, Jacob W Howe, et al.
Frontiers in Neuroscience|April 16, 2025
Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor functionSheila M Fleming, Sophia Scott, Edward J Hamad, et al.
NPJ Parkinson'S Disease|January 3, 2024
Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrilsJoseph R Patterson, Joseph Kochmanski, Anna C Stoll, et al.
JCI Insight|March 8, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's diseaseTracy A Cole, Hien Zhao, Timothy J Collier, et al.
Progress in Neurobiology|July 26, 2015
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F Bastide, Wassilios G Meissner, Barbara Picconi, et al.
Pageof 6